CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

Core Insights - CytoDyn Inc. announced positive clinical findings for leronlimab in patients with advanced metastatic colorectal cancer (mCRC), with 3 out of 5 patients showing at least a partial response, including one complete response [1][3] - Dr. Benjamin Weinberg will present the final results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain [2] - The results support the ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, with the first patient recently dosed and additional patients being enrolled [3][5] Clinical Significance - The findings from the compassionate use protocol highlight a favorable safety profile for leronlimab and its potential clinical benefits in mCRC [3] - If confirmed, leronlimab could be effective for a variety of solid tumor types, and it has shown promise as a "priming" agent for patients with low PD-L1 levels who are unresponsive to checkpoint inhibitors [4] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody targeting CCR5, with applications in oncology, infectious diseases, and autoimmune conditions [6]